■ Aerpio said a recently completed phase 2 trial in glaucoma patients showed that the change from baseline in diurnal mean IOP at day 28 in study eyes treated with razuprotafib BID plus latanoprost was statistically significant compared to those treated with latanoprost monotherapy. Further analysis of the results demonstrated that razuprotafib had a larger IOP reduction after longer duration dosing (28 days vs 14 days) consistent with its potential mechanism of repairing Schlemm’s canal.

Razuprotafib also produced larger IOP reductions in patients with higher starting IOP, or a 1.6 mmHg IOP reduction in patients with postwashout IOPs of >26 mmHg. The razuprotafib topical drops were well tolerated in this trial. Aerpio initially studied razoprofatib as a treatment for diabetic retinopathy. However, the drug failed to meet the primary endpoint in a phase 2b clinical trial. GP